Assembly Biosciences 2025 Q3 Earnings Narrows Losses by 52.3% Despite Revenue Surge

Assembly Biosciences (ASMB) reported fiscal 2025 Q3 earnings on Nov 10th, 2025, exceeding revenue expectations while narrowing losses. The company’s $10.79 million revenue and reduced per-share loss of $0.72 signaled operational improvements. Guidance remained in-line with prior expectations, emphasizing continued pipeline progress and extended cash runway.

Revenue

The total revenue of Assembly Biosciences surged by 57.6% to $10.79 million in 2025 Q3, compared to $6.84 million in 2024 Q3. The entire $10.79 million in Q3 2025 revenue came from collaboration revenue with a related party, reflecting deepened partnerships in its antiviral development programs.

Earnings/Net Income

Assembly Biosciences narrowed losses to $0.72 per share in 2025 Q3, a 52.3% improvement from a loss of $1.51 per share in 2024 Q3. The company reduced its net loss to $-9.20 million, down 4.3% from $-9.61 million in the prior-year period. Despite these improvements, the company has sustained losses for seven consecutive years, underscoring ongoing financial challenges.

Price Action

The stock price of Assembly Biosciences rose 1.17% during the latest trading day, 2.89% over the past week, and surged 19.57% month-to-date.

Post-Earnings Price Action Review

; INSERT

HERE (same line) THEN ADD

Post-earnings, Assembly Biosciences’ shares reflected renewed investor optimism, with the stock’s 19.57% monthly gain outpacing its 1.17% daily rise. The upward trajectory aligns with the company’s narrowing losses and $175 million equity financing, which bolstered its cash reserves to $232.6 million as of September 30, 2025. Analysts noted the stock’s RSI approaching overbought territory, suggesting potential volatility ahead.

CEO Commentary

Jason Okazaki, CEO and President of Assembly Bio, highlighted significant Q3 2025 progress, including positive interim results for ABI-5366 in reducing HSV-2 shedding. The $175 million equity raise supports advancing HSV and HDV programs into Phase 2, with Phase 1b enrollment completed for ABI-5366 and ABI-1179. Okazaki emphasized confidence in the company’s financial runway, extending operations into late 2027.

Guidance

The company anticipates additional HSV program data by year-end, including weekly ABI-1179 and monthly ABI-5366 cohorts. A Phase 2 study for ABI-5366 is slated for mid-2026. Cash reserves are projected to fund operations through late 2027, potentially extending to 2028 with Gilead payments or warrant exercises.

Additional News

Assembly Biosciences announced $175 million in equity financing, enabling Phase 2 trials for HSV and HDV programs. The company also shared positive Phase 1b data for ABI-4334, a next-generation capsid assembly modulator for hepatitis B, with favorable safety and antiviral activity. Additionally, interim results for ABI-5366 in reducing HSV-2 shedding reinforced its potential for future trials.